PATOU GARY 4

What Happened

• Gary Patou, a director of Xenon Pharmaceuticals (XENE), recorded RSU-related derivative transactions. On 2026-06-01, 2,645 restricted stock units (RSUs) vested and converted into common shares (exercise/conversion). Those 2,645 shares were then disposed/transferred as reported (disposition recorded at $0.00). On 2026-06-03 he was granted two RSU awards totaling 12,100 RSUs (10,507 + 1,593) reported as derivative acquisitions at $0.00. No open-market purchases or cash sales were reported; these are compensation-related transactions.

Key Details

• Transaction dates: 2026-06-01 (vesting/conversion + disposition of 2,645 shares); 2026-06-03 (grant of 10,507 and 1,593 RSUs).
• Prices/values reported: $0.00 / N/A (these reflect internal RSU settlement/grants; no market sale proceeds reported).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: The 2,645 shares represent RSUs granted 6/5/2025 that vested 100% on 6/1/2026.
  • F2: The disposition was to the "Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou."
  • F3/F4: The June 3 RSUs vest 100% on the earlier of 6/1/2027 or the day before the issuer's 2027 annual meeting; each RSU converts to one Common Share on vesting.
• Filing timeliness: Report filed 2026-06-03 for transactions on 6/1 and 6/3 — appears timely (no late filing flag reported).

Context

• These transactions involve RSU vesting and new RSU grants (derivative awards), which are routine equity compensation for insiders and not the same as an open-market buy or sell. The conversion/transfer recorded at $0.00 indicates internal settlement/transfer (to a family trust per F2), not a cash sale. Such compensation events are generally less informative about immediate insider market sentiment than open-market purchases.